Company Overview of Cellectis Bioresearch SAS
Cellectis bioresearch SAS focuses on the development of meganuclease-based targeted integration products for the generation of stable and isogenic cell lines for the drug discovery, gene function, and protein production markets. It offers genome customization toolkits, which include reagents and protocols that enable precise modifications of DNA sequences in a targeted genome, including a cell line, a primary or stem cell, or a whole organism; meganucleases, which are sequence-specific endonucleases; cGPS, a cellular genome positioning system; and cGPS custom targeted integration kits, which enable the engineering of cell lines for drug discovery, protein production, and gene function studie...
8 rue de la Croix Jarry
Founded in 2008
Key Executives for Cellectis Bioresearch SAS
Compensation as of Fiscal Year 2014.
Cellectis Bioresearch SAS Key Developments
Axxam and Cellectis Bioresearch Announce Their Collaboration to Offer a New Generation of Cell Based Assays
Jan 17 14
Axxam and Cellectis bioresearch have started a collaboration to offer to the Life Science industry an extensive range of integrated discovery services based on genomic engineering technologies. Under the joint offering, clients will be provided with a one-stop-shop approach for the generation of cell-based assays through genomic engineering. Genes of interest will be modified using Cellectis bioresearch's proprietary genome engineering technologies, after which functional cellular assays will be developed using Axxam's expertise and technologies for cell line generation. Both the required gene modification and the resulting functionality change will be experimentally demonstrated. Finally, validated assays for screening and profiling experiments will be provided to the client. With the currently available genome engineering technologies virtually any gene, at any position, in any cell type can be addressed for a wide range of applications such as knock-in insertions, knock-out deletions, reporter cell line generations and others.
Cellectis Bioresearch Launches Compact TALEN(TM)
Sep 23 13
Cellectis bioresearch announced the launch of a monomeric Compact TALEN(TM), that allows efficient transfection and genome editing in sensitive cells. Transfection of sensitive cells such as primary cells, plant cells and iPS cells is the major limitation for efficient genome editing. To breakdown this barrier, Cellectis scientists have developed a monomeric TALEN(TM), distributed under the name Compact TALEN(TM). In contrast to Custom TALEN(TM), the monomeric Compact TALEN(TM) requires the expression of only one DNA or RNA molecule to be active. This exquisite property, not only ease DNA/RNA cell transfection but offers a tremendous advantage to scientist who have to use viral shuttles for vectorization. This technology greatly simplifies the design and synthesis as well as the therapeutic delivery of nucleases. This new product based on Cellectis' proprietary TAL effector nuclease technology makes it possible to target specific DNA segments using just a single molecule.
Similar Private Companies By Industry
Recent Private Companies Transactions
July 29, 2014
Most Searched Private Companies
Sponsored Financial Commentaries